Clinical Trials

142 enrolled

Biliary Tract Neoplasms

NCT06282575 2026-03-24

Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer

286 enrolled

Biliary Tract Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma

NCT07221253 2026-03-17

AB02

1,100 enrolled

Biliary Tract Neoplasms, Gallbladder Neoplasms, Recurrence

NCT06109779 2026-03-04

Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01)

757 enrolled

Bile Duct Neoplasms, Biliary Tract Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma, Klatskin Tumor

NCT06591520 2026-01-21

AK112 Combined With Chemotherapy Versus Durvalumab Combined With Chemotherapy in Advanced Biliary Tract Cancer

682 enrolled

Biliary Tract Neoplasms

NCT07062263 2025-07-14

TAB-2

220 enrolled

Biliary Tract Neoplasms

NCT03478488 2025-05-29

KN035-BTC

480 enrolled

Biliary Tract Neoplasms

NCT05615818 2025-04-23

SAFIR-ABC10

800 enrolled

Biliary Tract Neoplasms

NCT03673072 2024-11-12

GAIN

Phase 3 Completed

68 enrolled

Biliary Tract Neoplasms

NCT04163900 2023-05-24

Comparing NUC-1031 Plus Cisplatin to Gemcitabine Plus Cisplatin in Patients With Advanced Biliary Tract Cancer

Phase 3 Terminated

773 enrolled 15 charts

Adenocarcinoma, Biliary Tract Neoplasms, Digestive System Neoplasms, Neoplasm Metastasis, Neoplasms, Cholangiocarcinoma

NCT04401709 2022-06-15

Gemcitabine+ Capecitabine Vs Capecitabine in Curatively Resected Biliary Tract Cancer

Phase 3 Unknown

490 enrolled

Biliary Tract Neoplasms

NCT02182778 2019-02-21

GEM/Cisplatin/S-1 vs GEM/Cisplatin for Biliary Tract Cancer

Phase 3 Completed

246 enrolled